Share This Page
Drug Price Trends for NDC 68599-2302
✉ Email this page to a colleague
Average Pharmacy Cost for 68599-2302
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ISOPROPYL RUBBING ALCOHOL 70% | 68599-2302-06 | 0.04534 | ML | 2025-12-17 |
| ISOPROPYL RUBBING ALCOHOL 70% | 68599-2302-06 | 0.04440 | ML | 2025-11-19 |
| ISOPROPYL RUBBING ALCOHOL 70% | 68599-2302-06 | 0.04495 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68599-2302
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68599-2302
Introduction
NDC 68599-2302 corresponds to Ado-trastuzumab emtansine (Kadcyla), a targeted antibody-drug conjugate (ADC) used in the treatment of HER2-positive breast cancer. Approved by the U.S. Food and Drug Administration (FDA) in 2013, Kadcyla represents a critical advancement in oncology therapeutics, merging trastuzumab with the cytotoxic agent emtansine to enhance efficacy and reduce systemic toxicity. Its market dynamics are shaped by factors such as clinical demand, competitive landscape, regulatory developments, and pricing strategies.
This analysis explores current market conditions, competitive landscape, pricing trends, and future price projections for NDC 68599-2302. It aims to provide healthcare industry stakeholders—including pharmaceutical manufacturers, payers, and healthcare providers—with actionable insights into Kadcyla's commercial outlook.
Market Overview
Therapeutic Indication and Patient Demand
Kadcyla primarily treats HER2-positive metastatic breast cancer, especially in patients who have previously received trastuzumab and chemotherapy. According to the American Cancer Society, approximately 15-20% of breast cancers overexpress HER2, translating to an estimated annual population of roughly 1.2 million new cases globally, with U.S. incidence around 300,000 annually.
The demand for Kadcyla is driven by:
- Clinical guidelines: It is recommended by NCCN and ASCO guidelines for second-line and certain adjuvant settings.
- Line of therapy: Increasing use in early and extended lines of treatment expands patient eligibility.
- Resistance and side-effect profile: Its targeted mechanism offers favorable tolerability compared with traditional chemotherapies.
Market Penetration and Competition
Kadcyla competes with other HER2-targeted therapies like trastuzumab (Herceptin), pertuzumab (Perjeta), and newer ADCs such as trastuzumab deruxtecan (Enhertu). While trastuzumab remains the backbone for HER2-positive breast cancer, Kadcyla's niche as an antibody-drug conjugate provides an improved clinical profile for certain patient subsets.
Global sales have shown consistent growth, with U.S. sales reaching approximately $1.3 billion in 2022[1]. Growth is sustained by increasing adoption and expanded indications, despite its higher price point relative to trastuzumab alone.
Pricing Analysis
Historical Pricing Trends
Kadcyla’s pricing has remained relatively stable but at a premium reflecting its innovation and clinical efficacy. As of 2022, the wholesale acquisition cost (WAC) per 100 mg vial was approximately $9,600, translating into a treatment course costing $10,000–$12,000 depending on dosage and frequency. Typical treatment involves an average of 4–6 cycles, resulting in a total cost ranging from $50,000 to $70,000 per patient.
Reimbursement Environment
The drug is often reimbursed via Medicare Part B or commercial payers, factoring in its high cost. Payers increasingly emphasize value-based arrangements, including outcomes-based contracts, to mitigate financial risk and improve patient access.
Market-Driven Price Factors
- Demand elasticity: During the COVID-19 pandemic, utilization temporarily declined but rebounded with protocol adjustments.
- Regulatory and policy pressures: Cost-effectiveness assessments by agencies like ICER influence pricing negotiations.
- Manufacturer strategies: Roche, the maker of Kadcyla, maintains premium pricing to recoup R&D investment and fund pipeline development.
Future Price Projections (2023–2028)
Key Drivers Affecting Future Pricing
- Competitive landscape evolution: Introduction of new ADCs and biosimilars (pending regulatory approval) may increase pricing pressure.
- Market expansion: Adoption in early-line settings and in broader geographic regions (e.g., Europe, Asia-Pacific) could influence volume but not necessarily price.
- Regulatory changes: Potential indications expansion could justify higher pricing or push for negotiated discounts.
- Cost-of-goods trends: Manufacturing efficiencies and supply chain negotiations could marginally impact pricing.
Projected Price Trends
Based on current market intelligence and historical pricing data, Kadcyla’s per-vial cost is projected to remain within the $9,500–$10,500 range through 2025. However, the average treatment course price may experience modest declines (3–5%) due to increased competition and payer negotiations by 2026–2028.
In a scenario where biosimilar trastuzumab gains broader adoption, the premium for Kadcyla relative to trastuzumab may diminish, influencing per-unit prices downward by approximately 10–15% over the next 3–5 years.
Market Growth & Pricing Impact
The overall market for HER2-targeted ADCs and combination therapies is anticipated to grow at a CAGR of 8–10% driven by increasing prevalence and expanded indications. Price stabilization or slight reductions are expected due to market maturation, competitive pressures, and value-based care initiatives.
Regulatory and Economic Considerations
- Potential biosimilar entrants: Pending FDA approval, biosimilars to trastuzumab could reduce overall treatment costs, indirectly affecting Kadcyla's market share and profitability.
- Value-based pricing: Pay-for-performance contracts could lead to tiered pricing models, with discounts linked to clinical outcomes.
- Legislative pressures: Congressional and payer-driven cost containment measures could influence future pricing policies.
Conclusion and Strategic Implications
Kadcyla (NDC 68599-2302) remains a high-value therapeutic with strong clinical demand, supported by its targeted mechanism and efficacy profile. While current pricing points reflect a premium positioning, future projections suggest a relatively stable price environment with potential reductions driven by biosimilar competition and market dynamics.
Healthcare stakeholders should monitor regulatory developments, emerging competition, and payer policies to adapt procurement and reimbursement strategies effectively. Companies planning to expand into ADC segments should consider the evolving pricing landscape and prioritize value-based contracting to sustain profitability.
Key Takeaways
- Stable yet premium-priced: Kadcyla’s pricing remains high but is likely to experience slight declines within the next 3–5 years.
- Market growth driven by indications expansion: Increased utilization in early-line settings and global adoption will support revenue growth despite pricing pressures.
- Competitive and biosimilar threats: Upcoming biosimilars, if approved, could significantly impact pricing and market share.
- Value-based contracting: Emphasis on outcome-based reimbursement models will influence future pricing strategies.
- Strategic positioning required: Stakeholders should align procurement, reimbursement, and clinical use policies with evolving market and regulatory environments.
FAQs
-
What is the current market price of Kadcyla?
The approximate treatment course costs range from $50,000 to $70,000, with per-vial prices around $9,600 as of 2022. -
How does Kadcyla compare cost-wise to trastuzumab?
Kadcyla’s cost per treatment course is significantly higher, often 3–4 times that of trastuzumab, justified by its targeted delivery of chemotherapy. -
Are biosimilars affecting Kadcyla’s pricing?
Biosimilar trastuzumab is anticipated to reduce trastuzumab costs, which may generate downward pressure on Kadcyla’s pricing due to substitution and payer preference shifts. -
What are the primary factors influencing Kadcyla’s future price?
Competition from new ADCs and biosimilars, market expansion, regulatory decisions, and payer negotiations are key drivers. -
Will Kadcyla’s price increase or decrease in the near future?
Prices are expected to remain relatively stable with slight declines anticipated due to market competition and cost containment efforts.
Sources
- IQVIA. U.S. Prescription Drug Market Data (2022).
- American Cancer Society. Breast Cancer Facts & Figures 2022.
- EvaluatePharma. World Preview of Oncology Drug Sales (2022).
- FDA. Kadcyla (Ado-trastuzumab emtansine) Approval Document (2013).
- Healthcare Payer Reports. Reimbursement and Pricing Trends in Oncology (2022).
More… ↓
